PBE vs XBI

Key Takeaways

• Invesco Biotechnology & Genome ETF (PBE) and SPDR S&P Biotech ETF (XBI) both target the biotechnology sector within healthcare but differ markedly in concentration and methodology.
• PBE follows a dynamic, tiered equal-weighted strategy with approximately 30-33 holdings, resulting in higher concentration in top positions compared to XBI's broader equal-weighted approach with 150-159 holdings.
• XBI offers lower costs with an expense ratio of 0.35% versus PBE's 0.58%, providing a more economical option for broad biotech exposure.
• PBE's structure emphasizes a smaller universe of biotechnology and genome-focused companies, while XBI provides diversified access across the S&P Biotechnology Select Industry Index.
• Both ETFs maintain nearly 100% allocation to healthcare, primarily biotechnology, exposing investors to similar sector risks including regulatory developments and innovation cycles.
• Structural differences in diversification and cost position XBI for broader market participation, whereas PBE suits investors seeking a more concentrated thematic approach.

Introduction

Investors seeking biotechnology exposure often compare Invesco Biotechnology & Genome ETF (PBE) and SPDR S&P Biotech ETF (XBI) due to their focused strategies within the healthcare sector. These exchange-traded funds (ETFs) do not compete directly in every respect but represent alternative approaches to capturing growth in biotechnology companies. PBE employs a dynamic selection methodology on a narrower set of holdings, while XBI delivers equal-weighted exposure to a larger universe of biotech firms. The comparison helps clarify trade-offs in diversification, costs, and thematic precision for portfolio construction in the evolving biotech landscape.

Invesco Biotechnology & Genome ETF (PBE) Overview

Invesco Biotechnology & Genome ETF (PBE) seeks to track the performance of the Dynamic Biotechnology & Genome Intellidex Index. This index selects approximately 30 U.S. biotechnology and genome companies principally engaged in research, development, manufacturing, and marketing of biotechnological products and services. The fund maintains a tiered equal-weighted structure, resulting in roughly 30-33 holdings. Sector allocation stands at nearly 100% healthcare, with the majority in biotechnology. Top holdings typically account for a significant portion of assets, reflecting moderate concentration. PBE operates as a passively managed ETF with an expense ratio of 0.58%. Its distinguishing feature lies in the dynamic index methodology that incorporates quantitative factors for security selection within the biotech and genome theme.

SPDR S&P Biotech ETF (XBI) Overview

SPDR S&P Biotech ETF (XBI) aims to replicate the total return of the S&P Biotechnology Select Industry Index. The index includes U.S.-listed biotechnology companies and applies a modified equal-weighting methodology. The ETF holds approximately 150-159 securities, providing broad diversification across small-, mid-, and large-capitalization biotech firms. Allocation remains almost entirely within healthcare, predominantly biotechnology. Top 10 holdings represent a smaller share of assets due to the equal-weight approach. XBI functions as a passively managed ETF with an expense ratio of 0.35%. Key structural characteristics include quarterly rebalancing to maintain equal weights and transparent daily holdings disclosure, emphasizing balanced participation across the sector.

Industry and Thematic Backdrop

The biotechnology sector operates within the broader healthcare industry, driven by advancements in genetic engineering, drug development, and personalized medicine. Macroeconomic factors such as interest rate expectations influence capital flows into growth-oriented biotech firms, while regulatory approvals and clinical trial outcomes serve as primary catalysts. Capital allocation trends favor companies with robust pipelines, and sector risks include high research and development costs, patent expirations, and potential policy changes affecting drug pricing. Both ETFs reflect these dynamics through their healthcare-centric mandates, positioning investors for exposure to innovation cycles and earnings variability inherent in the biotech space.

Performance and Positioning Comparison

In recent market cycles, the more concentrated structure of Invesco Biotechnology & Genome ETF (PBE) has led to greater sensitivity to movements in its top holdings, amplifying volatility relative to broader peers during earnings seasons or sector rotations. SPDR S&P Biotech ETF (XBI), with its wider diversification and equal-weighting, has exhibited smoother participation across biotech sub-themes, potentially mitigating single-stock impacts. Performance differentials often tie to interest rate environments affecting growth valuations and commodity or supply chain trends influencing manufacturing costs. XBI's lower expense ratio supports relative efficiency over longer horizons, while PBE's focused methodology may align with periods of strength in specific genome or biotechnology leaders.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the AI Screener to explore opportunities in biotech and other sectors.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would likely favor SPDR S&P Biotech ETF (XBI) in the current environment. Its lower expense ratio, broader diversification across approximately 150 holdings, and equal-weight methodology provide greater consistency and reduced single-stock risk within the biotech sector. These attributes support more stable positioning amid sector momentum and macroeconomic shifts compared to the higher-cost, more concentrated profile of Invesco Biotechnology & Genome ETF (PBE).

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations